Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
February 9, 2022
AAM
State of the Union: Generic and Biosimilar Savings for States and Taxpayers
Blog
February 6, 2022
AAM
Seven Reasons to Join Us for Access! 2022
Blog
January 26, 2022
AAM
Generic Prices Are Falling, But Seniors Are Paying More for Generic Drugs. What’s Happening Here?
Blog
January 4, 2022
AAM
AAM All Access Podcast: Bob Billings
Blog
December 20, 2021
AAM
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
Blog
December 14, 2021
Founders Series
Thank you, Ramprasad Reddy
Blog
December 3, 2021
AAM
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
Blog
December 2, 2021
AAM
How Inflation Penalties for Generic Medicines Could Worsen Drug Shortages
Blog
November 29, 2021
AAM
Process & Progress: A Recap of GRx+Biosims 2021
Blog
November 20, 2021
AAM
AAM All Access Podcast: Lachman Consultants’ Robert Pollock
Blog
November 15, 2021
AAM
Inflation Rebate Proposal Builds on Bad Policy for Generics
Blog
November 12, 2021
AAM
Medicare Negotiations Serve as a Catalyst to a Perpetual Monopoly
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
